The metabolic effects of tumor necrosis factor and other cytokines

[1]  A. Cerami,et al.  Selective inhibition of synthesis of enzymes for de novo fatty acid biosynthesis by an endotoxin-induced mediator from exudate cells. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[2]  W. Beisel,et al.  Hypertriglyceridemia produced by endotoxin: role of impaired triglyceride disposal mechanisms. , 1976, The Journal of infectious diseases.

[3]  H. Imura,et al.  Interleukin-6 stimulates the secretion of adrenocorticotropic hormone in conscious, freely-moving rats. , 1988, Biochemical and biophysical research communications.

[4]  C. Dinarello,et al.  Interleukin-1-induced anorexia in the rat. Influence of prostaglandins. , 1989, The Journal of clinical investigation.

[5]  A. Cerami,et al.  Effect of endotoxin-induced monokines on glucose metabolism in the muscle cell line L6. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[6]  D. Donner,et al.  Modulation of endogenous hormone action by recombinant human tumor necrosis factor. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[7]  D. Liggitt,et al.  Development of partial tolerance to the gastrointestinal effects of high doses of recombinant tumor necrosis factor-alpha in rodents. , 1987, The Journal of clinical investigation.

[8]  W. Beisel,et al.  Infection with Diplococcus pneumoniae and Salmonella typhimurium in monkeys: changes in plasma lipids and lipoproteins. , 1972, The Journal of infectious diseases.

[9]  S. Numa,et al.  Levels of acetyl coenzyme A carboxylase and its effectors in rat liver after short‐term fat‐free refeeding , 1973, FEBS letters.

[10]  R. Sapolsky,et al.  Interleukin-1 stimulates the secretion of hypothalamic corticotropin-releasing factor. , 1987, Science.

[11]  A. Oliff,et al.  Tumors secreting human TNF/cachectin induce cachexia in mice , 1987, Cell.

[12]  A. Waage,et al.  Detection of Tumour Necrosis Factor‐Like Cytotoxicity in Serum from Patients With Septicaemia but Not from Untreated Cancer Patients , 1986, Scandinavian journal of immunology.

[13]  A. Cerami,et al.  Lipoprotein lipase suppression in 3T3-L1 cells by an endotoxin-induced mediator from exudate cells. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[14]  P. Kern.  Recombinant human tumor necrosis factor does not inhibit lipoprotein lipase in primary cultures of isolated human adipocytes. , 1988, Journal of lipid research.

[15]  K. Burman,et al.  Alterations in thyroid function in patients with systemic illness: the "euthyroid sick syndrome". , 1982, Endocrine reviews.

[16]  S. Mahony,et al.  Induction of weight loss and metabolic alterations by human recombinant tumour necrosis factor. , 1988, British Journal of Cancer.

[17]  R. Harris,et al.  Short-term Hormonal Control of Hepatic Lipogenesis , 1980, Diabetes.

[18]  M. Serio,et al.  The effect of diet on tumor necrosis factor stimulation of hepatic lipogenesis. , 1990, Metabolism: clinical and experimental.

[19]  J. H. Shaw,et al.  Effect of sepsis on VLDL kinetics: responses in basal state and during glucose infusion. , 1985, The American journal of physiology.

[20]  J. Moss,et al.  Acetyl coenzyme A carboxylase. , 1974, Current topics in cellular regulation.

[21]  C. Dinarello,et al.  Immunoregulatory feedback between interleukin-1 and glucocorticoid hormones. , 1986, Science.

[22]  D. Rubinow,et al.  The neuroendocrine effects of interleukin-2 treatment. , 1989, The Journal of clinical endocrinology and metabolism.

[23]  C. Maury,et al.  Elevated levels of circulating cachectin/tumor necrosis factor in patients with acquired immunodeficiency syndrome. , 1988, The American journal of medicine.

[24]  J. Hershman,et al.  Impairment of hypothalamic-pituitary-thyroid function in rats treated with human recombinant tumor necrosis factor-alpha (cachectin). , 1989, Endocrinology.

[25]  C. Dinarello,et al.  Role of interleukin 1 and tumor necrosis factor on energy metabolism in rabbits. , 1988, The American journal of physiology.

[26]  M. Grieco,et al.  Tumor necrosis factor and HIV P24 antigen levels in serum of HIV-infected populations. , 1988, Journal of acquired immune deficiency syndromes.

[27]  D. Williamson,et al.  Tumour necrosis factor alpha (cachectin) mimics some of the effects of tumour growth on the disposal of a [14C]lipid load in virgin, lactating and litter-removed rats. , 1988, The Biochemical journal.

[28]  H. Schreiber,et al.  Synergy between tumor necrosis factor and bacterial products causes hemorrhagic necrosis and lethal shock in normal mice. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[29]  R. Lees,et al.  Effects of an experimental viral infection on plasma lipid and lipoprotein metabolism. , 1972, Metabolism: clinical and experimental.

[30]  A. Waage,et al.  ASSOCIATION BETWEEN TUMOUR NECROSIS FACTOR IN SERUM AND FATAL OUTCOME IN PATIENTS WITH MENINGOCOCCAL DISEASE , 1987, The Lancet.

[31]  J. Wang,et al.  Hypertriglyceridemia in the acquired immunodeficiency syndrome. , 1989, The American journal of medicine.

[32]  J. D. Albert,et al.  Shock and tissue injury induced by recombinant human cachectin. , 1986, Science.

[33]  J. Guckian,et al.  Role of metabolism in pathogenesis of bacteremia due to Diplococcus pneumoniae in rabbits. , 1973, The Journal of infectious diseases.

[34]  F. Szoka,et al.  Incorporation of LPS in Liposomes Diminishes Its Ability to Induce Tumoricidal Activity and Tumor Necrosis Factor Secretion in Murine Macrophages , 1988, Journal of leukocyte biology.

[35]  T. Ikejima,et al.  Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. , 1988, The Journal of clinical investigation.

[36]  K. Cantell,et al.  Effect of Interferon on Glucose Tolerance and Insulin Sensitivity , 1989, Diabetes.

[37]  W. Fiers,et al.  The toxic effects of tumor necrosis factor in vivo and their prevention by cyclooxygenase inhibitors. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[38]  J. Tavernier,et al.  Multiple effects of tumor necrosis factor on lipoprotein lipase in vivo. , 1987, The Journal of biological chemistry.

[39]  Neal Ra,et al.  Proceedings: Attempts to infect inbred strains of rats and mice with Entamoeba histolytica. , 1975 .

[40]  K. Feingold,et al.  Tumor necrosis factor-alpha stimulates hepatic lipogenesis in the rat in vivo. , 1987, The Journal of clinical investigation.

[41]  S. Mccann,et al.  Central action of interleukin‐1 in altering the release of tsh, growth hormone, and prolactin in the male rat , 1987, Journal of neuroscience research.

[42]  J. D. Albert,et al.  Cachectin/tumor necrosis factor induces lethal shock and stress hormone responses in the dog. , 1987, Surgery, gynecology & obstetrics.

[43]  E. Girardin,et al.  Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura. , 1988, The New England journal of medicine.

[44]  R. Krauss,et al.  Tumor necrosis factor acutely increases plasma levels of very low density lipoproteins of normal size and composition. , 1990, Endocrinology.

[45]  B. Aggarwal,et al.  Characterization of the in vitro and in vivo species preference of human and murine tumor necrosis factor-alpha. , 1988, Cancer research.

[46]  P. Hotez,et al.  Weight loss associated with an endotoxin-induced mediator from peritoneal macrophages: the role of cachectin (tumor necrosis factor). , 1985, Immunology letters.

[47]  B. Aggarwal,et al.  Interferons and tumor necrosis factors have similar catabolic effects on 3T3 L1 cells. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[48]  R. Egdahl,et al.  First annual Arnar-Stone lecture: The importance of the endocrine and metabolic responses to shock and trauma. , 1977, Critical care medicine.

[49]  J. Norton,et al.  Tumor necrosis factor: immune endocrine interaction. , 1989, Surgery.

[50]  C. Lang,et al.  Interleukin-1 induced increases in glucose utilization are insulin mediated. , 1989, Life sciences.

[51]  J. Norton,et al.  Cachectin/tumor necrosis factor: a possible mediator of cancer anorexia in the rat. , 1988, Cancer research.

[52]  R. I. Gregerman,et al.  Suppression of thyrotropin in the low-thyroxine state of severe nonthyroidal illness. , 1985, The New England journal of medicine.

[53]  S. Calvano,et al.  Hormonal and metabolic response to recombinant human tumor necrosis factor in rat: in vitro and in vivo. , 1988, The American journal of physiology.

[54]  J. Spitzer,et al.  Tumor necrosis factor increases in vivo glucose utilization of macrophage-rich tissues. , 1987, Biochemical and biophysical research communications.

[55]  K. Feingold,et al.  Effect of tumor necrosis factor (TNF) on lipid metabolism in the diabetic rat. Evidence that inhibition of adipose tissue lipoprotein lipase activity is not required for TNF-induced hyperlipidemia. , 1989, The Journal of clinical investigation.

[56]  G. Moberg.  Site of action of endotoxins on hypothalamic-pituitary-adrenal axis. , 1971, The American journal of physiology.

[57]  C. Rouzer,et al.  Hypertriglyceridemia associated with Trypanosoma brucei brucei infection in rabbits: role of defective triglyceride removal. , 1980, Molecular and biochemical parasitology.

[58]  P. Pekala,et al.  Regulation of lipoprotein lipase synthesis and 3T3-L1 adipocyte metabolism by recombinant interleukin 1. , 1986, Biochimica et biophysica acta.

[59]  A. Cerami,et al.  Cachectin (Tumor Necrosis Factor) , 1988 .

[60]  B. Beutler,et al.  Recombinant interleukin 1 suppresses lipoprotein lipase activity in 3T3-L1 cells. , 1985, Journal of immunology.

[61]  A. Goldberg,et al.  Tumor necrosis factor can induce fever in rats without activating protein breakdown in muscle or lipolysis in adipose tissue. , 1988, The Journal of clinical investigation.

[62]  K. Tracey,et al.  Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation , 1988, The Journal of experimental medicine.

[63]  J. Kuhn,et al.  Tumor necrosis factor not detectable in patients with clinical cancer cachexia. , 1988, Journal of the National Cancer Institute.

[64]  W. Beisel,et al.  Metabolic response to infection. , 1975, Annual review of medicine.

[65]  M. Lumpkin.  The regulation of ACTH secretion by IL-1. , 1987, Science.

[66]  K. Feingold,et al.  Mechanisms by which tumor necrosis factor stimulates hepatic fatty acid synthesis in vivo. , 1988, Journal of lipid research.

[67]  J. Gallin,et al.  Serum lipids in infection. , 1969, The New England journal of medicine.

[68]  J. Gabrilove,et al.  The acute metabolic effects of tumor necrosis factor administration in humans. , 1987, Archives of surgery.

[69]  D. Wilmore,et al.  Tumor necrosis factor enhances glucose uptake by peripheral tissues. , 1989, The American journal of physiology.

[70]  S. H. Socher,et al.  Recombinant human tumor necrosis factor induces acute reductions in food intake and body weight in mice , 1988, The Journal of experimental medicine.

[71]  P. Pekala,et al.  Model for cachexia in chronic disease: secretory products of endotoxin-stimulated macrophages induce a catabolic state in 3T3-L1 adipocytes. , 1984, Transactions of the Association of American Physicians.

[72]  C. Dinarello,et al.  Direct stimulation of the adrenal cortex by interleukin-1. , 1987, Surgery.

[73]  C. Long.  Energy balance and carbohydrate metabolism in infection and sepsis. , 1977, The American journal of clinical nutrition.

[74]  H. Besedovsky,et al.  Antidiabetic effects of interleukin 1. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[75]  W. Vale,et al.  In the Rat, Interleukin- lα and -β Stimulate Adrenocorticotropin and Catecholamine Release* , 1989 .

[76]  Dubuis Jm,et al.  Human Recombinant Interleukin-1β Decreases Plasma Thyroid Hormone and Thyroid Stimulating Hormone Levels in Rats , 1988 .

[77]  K. Feingold,et al.  Evidence for two classes of cytokines that stimulate hepatic lipogenesis: relationships among tumor necrosis factor, interleukin-1 and interferon-alpha. , 1990, Endocrinology.

[78]  P. Scuderi,et al.  RAISED SERUM LEVELS OF TUMOUR NECROSIS FACTOR IN PARASITIC INFECTIONS , 1986, The Lancet.

[79]  S. Banks,et al.  Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. , 1989, The New England journal of medicine.

[80]  J. Norton,et al.  Reversal of the toxic effects of cachectin by concurrent insulin administration. , 1989, The American journal of physiology.

[81]  S. Grossberg,et al.  Interferon inhibits the conversion of 3T3-L1 mouse fibroblasts into adipocytes. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[82]  C. Nathan,et al.  Secretory products of macrophages. , 1987, The Journal of clinical investigation.

[83]  S. Fried,et al.  Cachectin/tumor necrosis factor decreases human adipose tissue lipoprotein lipase mRNA levels, synthesis, and activity. , 1989, Journal of lipid research.

[84]  H. Besedovsky,et al.  Corticotropin-releasing factor-producing neurons in the rat activated by interleukin-1. , 1987, Science.

[85]  A. Sakurai,et al.  Relationship of hypoglycemia to tumor necrosis factor production and antitumor activity: role of glucose, insulin, and macrophages. , 1985, Journal of the National Cancer Institute.

[86]  F. López‐Soriano,et al.  Comparative effects of tumour necrosis factor-alpha (cachectin), interleukin-1-beta and tumour growth on amino acid metabolism in the rat in vivo. Absorption and tissue uptake of alpha-amino[1-14C]isobutyrate. , 1989, The Biochemical journal.

[87]  C. Galanos,et al.  Growing tumors induce hypersensitivity to endotoxin and tumor necrosis factor , 1987, Infection and immunity.

[88]  J. Tavernier,et al.  EVIDENCE FOR TUMOUR NECROSIS FACTOR/CACHECTIN PRODUCTION IN CANCER , 1987, The Lancet.

[89]  P. Peterson,et al.  Tumor Necrosis Factor-α is a Potent ACTH Secretagogue: Comparison to Interleukin-1β , 1989 .

[90]  A. F. Muller,et al.  Human recombinant interleukin-1 beta and -alpha, but not recombinant tumor necrosis factor alpha stimulate ACTH release from rat anterior pituitary cells in vitro in a prostaglandin E2 and cAMP independent manner. , 1988, Neuroendocrinology.

[91]  K. Feingold,et al.  Effect of tumor necrosis factor administration in vivo on lipoprotein lipase activity in various tissues of the rat. , 1989, Journal of lipid research.

[92]  M. Serio,et al.  Multiple cytokines stimulate hepatic lipid synthesis in vivo. , 1989, Endocrinology.

[93]  J. Spitzer,et al.  Glucose kinetics and body temperature after lethal and nonlethal doses of endotoxin. , 1985, The American journal of physiology.

[94]  K. Feingold,et al.  Diet affects the mechanisms by which TNF stimulates hepatic triglyceride production. , 1990, The American journal of physiology.

[95]  H. Besedovsky,et al.  Interleukin 1 affects glucose homeostasis. , 1987, The American journal of physiology.

[96]  D. Spriggs,et al.  Chronic TNF Infusion Causes Anorexia But Not Accelerated Nitrogen Loss , 1989, Annals of surgery.

[97]  A. Cerami,et al.  Studies of endotoxin-induced decrease in lipoprotein lipase activity , 1981, The Journal of experimental medicine.

[98]  R. Krishnan,et al.  Effects of γ-Interferon on the Endocrine System: Results from a Phase I Study , 1987 .

[99]  M. Kawakami,et al.  Human recombinant TNF suppresses lipoprotein lipase activity and stimulates lipolysis in 3T3-L1 cells. , 1987, Journal of biochemistry.

[100]  G. Snyder,et al.  Cachectin alters anterior pituitary hormone release by a direct action in vitro. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[101]  M. Serio,et al.  Tumor necrosis factor stimulates hepatic lipid synthesis and secretion. , 1989, Endocrinology.

[102]  W. Pardridge,et al.  Thyroid function in nonthyroidal illnesses. , 1983, Annals of internal medicine.

[103]  J. Gamble,et al.  The effects of recombinant tumour necrosis factor (cachectin) on metabolism in isolated rat adipocyte, hepatocyte and muscle preparations. , 1987, The Biochemical journal.

[104]  K. Foon,et al.  A multiple-dose phase I trial of recombinant leukocyte A interferon in cancer patients. , 1982, JAMA.

[105]  K. Tracey,et al.  Cachectin: a hormone that triggers acute shock and chronic cachexia. , 1988, The Journal of infectious diseases.

[106]  W. Vale,et al.  In the mouse, the activation of the hypothalamic-pituitary-adrenal axis by a lipopolysaccharide (endotoxin) is mediated through interleukin-1. , 1989, Endocrinology.

[107]  P. Pekala,et al.  Regulation of lipoprotein lipase synthesis in 3T3-L1 adipocytes by cachectin. Further proof for identity with tumour necrosis factor. , 1986, The Biochemical journal.

[108]  C. Liedtke.  Differentiated properties of rabbit tracheal epithelial cells in primary culture. , 1988, The American journal of physiology.

[109]  E. Shiloni,et al.  Mechanism of the hypertriglyceridemia induced by tumor necrosis factor administration to rats. , 1989, Biochimica et biophysica acta.

[110]  M. Kawakami,et al.  Effects of Tumor Necrosis Factor-α/Cachectin on Thyroid Hormone Metabolism in Mice , 1988 .

[111]  K. Kasono,et al.  Effect of interleukin-1 (IL-1) on thyroid hormone metabolism in mice: stimulation by IL-1 of iodothyronine 5'-deiodinating activity (type I) in the liver. , 1989, Endocrinology.

[112]  A. Arimura,et al.  Interleukin-1 stimulates ACTH release by an indirect action which requires endogenous corticotropin releasing factor. , 1987, Endocrinology.

[113]  C. Nathan,et al.  Phase I trial of recombinant interferon gamma in cancer patients. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[114]  B. Beutler,et al.  Cachectin and tumour necrosis factor as two sides of the same biological coin , 1986, Nature.

[115]  F. López‐Soriano,et al.  Interleukin-1 and lipid metabolism in the rat. , 1989, The Biochemical journal.

[116]  M. Serio,et al.  Persistence of the hypertriglyceridemic effect of tumor necrosis factor despite development of tachyphylaxis to its anorectic/cachectic effects in rats. , 1989, Cancer research.